PURPOSE: Depression commonly accompanies diabetes, resulting in reduced adherence to medications and increased risk for morbidity and mortality. The objective of this study was to examine whether a simple, brief integrated approach to depression and type 2 diabetes mellitus (type 2 diabetes) treatment improved adherence to oral hypoglycemic agents and antidepressant medications, glycemic control, and depression among primary care patients. METHODS: We undertook a randomized controlled trial conducted from April 2010 through April 2011 of 180 patients prescribed pharmacotherapy for type 2 diabetes and depression in primary care. Patients were randomly assigned to an integrated care intervention or usual care. Integrated care managers collaborated with physicians to offer education and guideline-based treatment recommendations and to monitor adherence and clinical status. Adherence was assessed using the Medication Event Monitoring System (MEMS). We used glycated hemoglobin (HbA(1c)) assays to measure glycemic control and the 9-item Patient Health Questionnaire (PHQ-9) to assess depression. RESULTS: Intervention and usual care groups did not differ statistically on baseline measures. Patients who received the intervention were more likely to achieve HbA(1c) levels of less than 7% (intervention 60.9% vs. usual care 35.7%; P < .001) and remission of depression (PHQ-9 score of less than 5: intervention 58.7% vs. usual care 30.7%; P < .001) in comparison with patients in the usual care group at 12 weeks. CONCLUSIONS: A randomized controlled trial of a simple, brief intervention integrating treatment of type 2 diabetes and depression was successful in improving outcomes in primary care. An integrated approach to depression and type 2 diabetes treatment may facilitate its deployment in real-world practices with competing demands for limited resources.
RCT Entities:
PURPOSE:Depression commonly accompanies diabetes, resulting in reduced adherence to medications and increased risk for morbidity and mortality. The objective of this study was to examine whether a simple, brief integrated approach to depression and type 2 diabetes mellitus (type 2 diabetes) treatment improved adherence to oral hypoglycemic agents and antidepressant medications, glycemic control, and depression among primary care patients. METHODS: We undertook a randomized controlled trial conducted from April 2010 through April 2011 of 180 patients prescribed pharmacotherapy for type 2 diabetes and depression in primary care. Patients were randomly assigned to an integrated care intervention or usual care. Integrated care managers collaborated with physicians to offer education and guideline-based treatment recommendations and to monitor adherence and clinical status. Adherence was assessed using the Medication Event Monitoring System (MEMS). We used glycated hemoglobin (HbA(1c)) assays to measure glycemic control and the 9-item Patient Health Questionnaire (PHQ-9) to assess depression. RESULTS: Intervention and usual care groups did not differ statistically on baseline measures. Patients who received the intervention were more likely to achieve HbA(1c) levels of less than 7% (intervention 60.9% vs. usual care 35.7%; P < .001) and remission of depression (PHQ-9 score of less than 5: intervention 58.7% vs. usual care 30.7%; P < .001) in comparison with patients in the usual care group at 12 weeks. CONCLUSIONS: A randomized controlled trial of a simple, brief intervention integrating treatment of type 2 diabetes and depression was successful in improving outcomes in primary care. An integrated approach to depression and type 2 diabetes treatment may facilitate its deployment in real-world practices with competing demands for limited resources.
Authors: Julienne K Kirk; Ralph B D'Agostino; Ronny A Bell; Leah V Passmore; Denise E Bonds; Andrew J Karter; K M Venkat Narayan Journal: Diabetes Care Date: 2006-09 Impact factor: 19.112
Authors: Michael Von Korff; Wayne Katon; Elizabeth H B Lin; Gregory Simon; Evette Ludman; Malia Oliver; Paul Ciechanowski; Carolyn Rutter; Terry Bush Journal: Psychosom Med Date: 2005 Mar-Apr Impact factor: 4.312
Authors: John W Williams; Martha Gerrity; Tracey Holsinger; Steve Dobscha; Bradley Gaynes; Allen Dietrich Journal: Gen Hosp Psychiatry Date: 2007 Mar-Apr Impact factor: 3.238
Authors: Mercedes R Carnethon; Leslie S Kinder; Joan M Fair; Randall S Stafford; Stephen P Fortmann Journal: Am J Epidemiol Date: 2003-09-01 Impact factor: 4.897
Authors: Wayne J Katon; Michael Von Korff; Elizabeth H B Lin; Greg Simon; Evette Ludman; Joan Russo; Paul Ciechanowski; Edward Walker; Terry Bush Journal: Arch Gen Psychiatry Date: 2004-10
Authors: Heidemarie Abrahamian; Alexandra Kautzky-Willer; Angelika Rießland-Seifert; Peter Fasching; Christoph Ebenbichler; Peter Hofmann; Hermann Toplak Journal: Wien Klin Wochenschr Date: 2016-04 Impact factor: 1.704
Authors: Mohamad Adam Bujang; Mastura Ismail; Nur Khairul Bariyyah Mohd Hatta; Siti Haslina Othman; Nurakmal Baharum; Siti Sara Mat Lazim Journal: Malays J Med Sci Date: 2017-08-18
Authors: Heidemarie Abrahamian; Alexandra Kautzky-Willer; Angelika Rießland-Seifert; Peter Fasching; Christoph Ebenbichler; Peter Hofmann; Hermann Toplak Journal: Wien Klin Wochenschr Date: 2012-12 Impact factor: 1.704
Authors: Chiung-Yu Huang; Hui-Ling Lai; Chun-I Chen; Yung-Chuan Lu; Su-Chen Li; Long-Whou Wang; Yi Su Journal: Qual Life Res Date: 2015-10-26 Impact factor: 4.147